A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma. Issue 2 (August 2017)

• Record Type: Journal Article
• Authors: Guttmann, David M.; Frick, Melissa A.; Carmona, Ruben; Deville, Curtiland; Levin, William P.; Berman, Abigail T.; Chinniah, Chidambaram; Hahn, Stephen M.; Plastaras, John P.; Simone, Charles B.
• Is Part Of: Radiotherapy and oncology. Volume 124:Issue 2(2017:Aug.)
• Page Start: 271
• Page End: 276
• Publication Date: 2017-08
• Subjects: Sarcoma -- Reirradiation -- Proton therapy; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2017.06.024
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background and purpose: Proton reirradiation for sarcoma has not been previously described. We hypothesized that this strategy would provide favorable toxicity and survival outcomes. Material and methods: Patients with soft tissue sarcoma in a previously-irradiated field were enrolled on a prospective trial of proton reirradiation. The primary endpoint was provider-reported acute toxicity. Secondary endpoints included late toxicities, local control, and overall survival. Results: 23 patients underwent proton reirradiation. Median time between radiation courses was 40.7 months (range 10–272). No grade 4–5 toxicities were observed. One patient (4%) experienced acute grade 3 dysphagia. Common grade 2 acute toxicities were fatigue (26%), anorexia (17%), and urinary incontinence (13%). There were two grade 3 late wound infections (10%) and one grade 3 late wound complication (5%). Grade 2 late complications included lymphedema (10%), fracture (5%), and fibrosis (5%). At a median follow-up of 36 months, the 3-year cumulative incidence of local failure was 41% (95% CI [20–63%]). Median overall survival and progression-free survival were 44 and 29 months, respectively. In extremity patients, amputation was spared in 7/10 (70%). Conclusions: Proton reirradiation of recurrent/secondary soft tissue sarcomas is well tolerated. While longer follow-up is needed, early survival outcomes in this high-risk population are encouraging.